Drug Type Monoclonal antibody |
Synonyms FG-M108, M 108 |
Target |
Mechanism CLDN18.2 inhibitors(Claudin 18.2 inhibitors) |
Therapeutic Areas |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
CLDN18.2 positive Gastroesophageal junction adenocarcinoma | Phase 3 | CN | 04 Dec 2023 | |
CLDN18.2 positive stomach adenocarcinoma | Phase 3 | CN | 04 Dec 2023 | |
Gastrointestinal Neoplasms | Phase 2 | - | - | |
Pancreatic Cancer | Phase 2 | - | - | |
Advanced Malignant Solid Neoplasm | Phase 1 | CN | 11 Jun 2021 | |
Bile Duct Neoplasms | Phase 1 | - | - | |
Pancreatic carcinoma non-resectable | IND Approval | CN | 19 Apr 2024 |
CTR20210508 (ESMO2024) Manual | Phase 1 | 35 | FG-M108 plus gemcitabine and nab-paclitaxel | ubzlsivjui(thgatlyncf) = The most common were nausea (54.3%), emesis (51.4%) and hypoalbuminemia (42.9%). bofefqwfph (idlvdmzjnq ) | Positive | 16 Sep 2024 | |
NCT04894825 (ESMO2024) Manual | Phase 1/2 | 52 | FG-M108 plus CAPOX | uvixpyosdo(pavtdgguuf) = okyjkyasws aohbftmiie (bzulatdxpu ) View more | Positive | 16 Sep 2024 | |
(ipytcolceg) = vecrsnoxpb ldwaoyhptg (liimyylzri, 3.9 - 5.6) | |||||||
NCT06177041 (ASCO2024) Manual | Phase 1/2 | CLDN18.2 positive Gastroesophageal junction adenocarcinoma | CLDN18.2 positive Stomach Cancer First line CLDN18.2 Positive | HER2 Negative | 52 | FG-M108 plus CAPOX | ousvhjszwg(pemxevvmlo) = cdbxsieqdm strsrmbxkg (nzurxpknnn ) View more | Positive | 24 May 2024 |
FG-M108 plus CAPOX (low CLDN18.2 expressions (IHC 1+/2+/3+ ≥10% & 2+/3+ <40%)) | ousvhjszwg(pemxevvmlo) = oxkjvkwvaz strsrmbxkg (nzurxpknnn ) View more |